Trial · NCT06547944
Zanubrutinib, Obinutuzumab and Lenalidomide in Newly Diagnosed Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)
NCT06547944, Phase 1, Active not recruiting, Institute of Hematology & Blood Diseases Hospital, China
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Zanubrutinib, Obinutuzumab and Lenalidomide in Newly Diagnosed Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL). Trials, record NCT06547944. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT06547944
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Zanubrutinib, Obinutuzumab and Lenalidomide in Newly Diagnosed Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)
- NCT number
- NCT06547944
- Status
- Active not recruiting
- Phases
- Phase 1
- Enrollment
- 30 participants, estimated
- Lead sponsor
- Institute of Hematology & Blood Diseases Hospital, China
- Conditions
- Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Newly Diagnosed
- Interventions
- Zanubrutinib, Lenalidomide, Obinutuzumab
- First posted
- 2024-08-09
- Last updated
- 2024-08-09
Source ClinicalTrials.gov
Registered outcomes6
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Maximum Tolerated Dose (MTD) of lenalidomide in combination regimens were determined in newly diagnosed CLL/SLL patients, | From the date of first dose of study drugs until RP2D was determined(Approximately 4 months)] | |
| Primary | The incidence, nature and severity of adverse events (AE) were determined according to NCI-CTCAE v5.0 evaluation criteria | From first dose to 30 days after the last dose of Zanubrutinib or lenalidomide or Obinutuzumab | |
| Secondary | overall response rate(ORR) | From first dose to 30 days after the last dose of Zanubrutinib or lenalidomide or Obinutuzumab | Defined as the proportion of patients assessed as CR, CRi, or PR according to the IWCLL 2018 criteria at or before initiation of subsequent antitumor therapy. |
| Secondary | overall survival Overall survival(OS) | Up to 5 years | Defined as the time interval from enrollment to death for patients in an intentional-treatment population (ITT). If the patient continues to survive or if his or her life is unknown, the date of death will be the nearest point in time when the patient is known to be alive. |
| Secondary | Progress-free survival(PFS) | Up to 5 years | Defined as the time interval from enrollment to disease progression or death of a patient in an intention-to-treat population (ITT), whichever comes first. For those who did not progress at the time of exit or whose time to disease progression was not recorded, the last examination date was used as the end date. |
| Secondary | Duration of tumor remission(DOR) | Up to 5 years | Defined as the time interval between first recorded disease remission and first recorded evidence of PD in patients in an intention-to-treat population (ITT). No progression or time to disease progression was recorded at the time of exit from the trial, with the date of last examination as the end date. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers5
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT06547944
GET https://conductscience.org/api/trials/v1/NCT06547944/registered